文献速递癫痫

儿童耐药性癫痫手术评估前更多药物试验的相关因素及术后结局

Factors Associated With More Medication Trials Before Surgical Evaluation and Postsurgical Outcomes in Pediatric Drug-Resistant Epilepsy.
PubMed 文献 · Neurology · 2025-10-07

基于美国24个儿童癫痫中心1767例患儿的回顾性分析显示,54.6%的患儿在失败超过2种抗癫痫发作药物后才启动手术评估,遗传病因、全面性发作、每日发作、多种发作类型、MRI正常及神经系统查体异常与更晚评估独立相关。晚评估组无发作率显著更低(39.3% vs 60.8%),但80%患者术后发作减少超过50%。

要点

  • 超过半数儿童耐药性癫痫患者在失败超过2种药物后才启动手术评估。
  • 遗传病因、全面性发作、每日发作、多种发作类型、MRI正常及查体异常与更晚评估相关。
  • 晚评估与无发作率降低独立相关,但多数患者术后发作仍减少超过50%。

核心结论

  • 手术评估前失败超过2种抗癫痫发作药物与更复杂的癫痫表型和更低的无发作率独立相关。
  • 即使无发作可能性较低,及时癫痫手术仍可使80%的晚评估患者发作减少超过50%。

研究设计与样本

  • 回顾性分析儿科癫痫研究联盟手术数据库,纳入24个美国儿童癫痫中心。
  • 纳入2018年1月至2023年2月启动癫痫手术评估的18岁及以下儿童,共1767例。
  • 以首次I期评估前抗癫痫发作药物失败数量(≤2 vs >2)定义评估时机,采用多因素logistic回归分析。

主要发现

  • 802例(45.4%)在失败≤2种药物后启动评估,965例(54.6%)在失败>2种药物后启动评估。
  • 两组中位癫痫发作起始年龄分别为5.96岁和4.00岁。
  • 与更晚启动手术评估独立相关的因素包括遗传病因(OR 1.83,95%CI 1.28-2.60)、全面性发作(OR 2.64,95%CI 1.58-4.40)、每日发作(OR 1.69,95%CI 1.33-2.14)、多种发作类型(OR 1.59,95%CI 1.39-1.82)、MRI正常(OR 1.82,95%CI 1.52-2.18)及神经系统查体异常(OR 2.44,95%CI 2.01-2.96)。
  • 两组手术干预率相似(约50%)。
  • 失败≤2种药物后启动评估的患者无发作率显著更高(60.8% vs 39.3%,p < 0.001)。

临床怎么用

  • 指南推荐在2种适当抗癫痫发作药物失败后启动手术评估,临床应据此及时转诊。
  • 对于遗传病因、全面性发作、每日发作、多种发作类型、MRI正常或查体异常的患儿,应警惕评估延迟风险。
  • 即使无发作可能性较低,及时手术仍可能使发作减少超过50%,不应因表型复杂而延迟评估。

局限性

  • 本研究为回顾性分析,存在选择偏倚和信息偏倚可能。
  • 仅纳入美国儿科癫痫中心数据,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite strong evidence supporting timely surgical evaluation, many children with drug-resistant epilepsy undergo multiple antiseizure medication (ASM) trials before surgery. Because guidelines recommend evaluation after failure of 2 appropriate ASMs, evaluation after failure of >2 ASMs serves as a clinically relevant benchmark. The aim of this study was to identify factors associated with initiation of surgical evaluation after failure of >2 ASMs and evaluate its association with seizure freedom. METHODS: We performed a retrospective analysis using the Pediatric Epilepsy Research Consortium Surgery Database, including 24 US pediatric epilepsy centers. Children aged 18 years and younger who initiated epilepsy surgery evaluation between January 2018 and February 2023 were included. Timing of evaluation was defined by the number of ASM failures before first phase I evaluation (≤2 vs >2). Unadjusted analyses and multivariable logistic regression were used to identify predictors of later evaluation and assess its association with seizure freedom, adjusting for etiology, seizure type, MRI findings, and surgical procedure. RESULTS: Among 1,767 patients, 802 (45.4%) initiated surgical evaluation after failing ≤2 ASMs and 965 (54.6%) after failing >2 ASMs, with a median age at seizure onset of 5.96 and 4.00 years, respectively. Factors independently associated with later initiation of surgical evaluation included genetic etiology (odds ratio [OR] 1.83, 95% CI 1.28-2.60), generalized seizures (OR 2.64, 95% CI 1.58-4.40), daily seizures (OR 1.69, 95% CI 1.33-2.14), multiple seizure types (OR 1.59, 95% CI 1.39-1.82), normal MRI (OR 1.82, 95% CI 1.52-2.18), and abnormal neurologic examination (OR 2.44, 95% CI 2.01-2.96). Surgical intervention rates were similar (∼50%) between groups. Patients who initiated surgical evaluation after failure of ≤2 ASMs had significantly higher seizure freedom rates (60.8% vs 39.3%, p < 0.001). On multivariable analysis, failure of >2 ASMs before surgical evaluation was independently associated with lower odds of seizure freedom (OR 0.66, 95% CI 0.45-0.96, p = 0.028). DISCUSSION: Initiation of surgical evaluation after failure of more than 2 ASMs is associated with more complex epilepsy phenotypes and lower rates of seizure freedom. However, 80% of these patients still experienced a >50% reduction in seizures, highlighting the therapeutic benefits of timely epilepsy surgery-even when seizure freedom is unlikely-regardless of epilepsy subtype.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Samanta D, Newell G, Caraway AR, et al. Factors Associated With More Medication Trials Before Surgical Evaluation and Postsurgical Outcomes in Pediatric Drug-Resistant Epilepsy. Neurology. 2025. PMID: 41056528. doi:10.1212/WNL.0000000000214198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。